PBH - Prestige Consumer Healthcare Inc.
NYSE
->
Healthcare
->
Medical Distribution
Tarrytown,
United States
Type: Equity
PBH price evolution
PBH
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $34.26 | $46.47 | $63.62 | |
| Short term investments | ||||
| Net receivables | $171.69 | $176.78 | $174.29 | |
| Inventory | $152.04 | $138.72 | $148.64 | |
| Total current assets | $368.74 | $375.04 | $393.79 | |
| Long term investments | ||||
| Property, plant & equipment | $86.28 | $89.33 | $83.26 | |
| Goodwill & intangible assets | $2846.26 | $2848.32 | $2856.41 | |
| Total noncurrent assets | $2938.78 | $2943.37 | $2945.97 | |
| Total investments | ||||
| Total assets | $3307.52 | $3318.42 | $3339.75 | |
| Current liabilities | ||||
| Accounts payable | $39.56 | $38.98 | $39.34 | |
| Deferred revenue | ||||
| Short long term debt | $4.45 | $6.15 | $7.84 | |
| Total current liabilities | $114.11 | $117.05 | $127.44 | |
| Long term debt | $1091.36 | $1133.5 | $1205.67 | |
| Total noncurrent liabilities | $1512.63 | $1546.29 | $1611.74 | |
| Total debt | $1102.86 | $1139.66 | $1213.51 | |
| Total liabilities | $1626.75 | $1663.33 | $1739.18 | |
| Shareholders' equity | ||||
| Retained earnings | $1390.27 | $1341.2 | $1291.74 | |
| Other shareholder equity | -$31.34 | -$34.49 | -$28.53 | |
| Total shareholder equity | $1680.77 | $1655.08 | $1600.58 | |
| (in millions $) | 31 Dec 2024 | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $46.47 | $58.49 | $27.18 | $32.3 |
| Short term investments | ||||
| Net receivables | $176.78 | $167.02 | $139.33 | $114.67 |
| Inventory | $138.72 | $162.12 | $120.34 | $114.96 |
| Total current assets | $375.04 | $391.74 | $293.27 | $269.83 |
| Long term investments | ||||
| Property, plant & equipment | $89.33 | $89.53 | $98.53 | $102.77 |
| Goodwill & intangible assets | $2848.32 | $2869.45 | $3275.61 | $3053.81 |
| Total noncurrent assets | $2943.37 | $2961.99 | $3377.41 | $3159.44 |
| Total investments | ||||
| Total assets | $3318.42 | $3353.73 | $3670.68 | $3429.27 |
| Current liabilities | ||||
| Accounts payable | $38.98 | $62.74 | $55.76 | $45.98 |
| Deferred revenue | ||||
| Short long term debt | $6.15 | $9.76 | $9.11 | $8.45 |
| Total current liabilities | $117.05 | $160.72 | $143.42 | $122.14 |
| Long term debt | $1133.5 | $1357.33 | $1497.25 | $1506.17 |
| Total noncurrent liabilities | $1546.29 | $1745.93 | $1949.65 | $1948.84 |
| Total debt | $1139.66 | $1367.09 | $1506.36 | $1514.62 |
| Total liabilities | $1663.33 | $1906.64 | $2093.07 | $2070.97 |
| Shareholders' equity | ||||
| Retained earnings | $1341.2 | $1131.86 | $1214.16 | $1008.78 |
| Other shareholder equity | -$34.49 | -$31.56 | -$19.03 | -$19.8 |
| Total shareholder equity | $1655.08 | $1447.08 | $1577.61 | $1358.3 |
| (in millions $) | 30 Jul 2025 | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | ||||
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | ||||
| Income (for common shares) | ||||
| (in millions $) | 31 Dec 2024 | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1125.36 | $1127.72 | $1086.81 | $943.37 |
| Cost of revenue | $500.91 | $502.43 | $466.17 | $395.89 |
| Gross Profit | $624.45 | $625.29 | $620.65 | $547.47 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | $259.47 | $252.41 | $265.86 | $226.13 |
| Total operating expenses | $282.02 | $647.71 | $290.73 | $250.07 |
| Operating income | $342.43 | -$22.41 | $329.92 | $297.4 |
| Income from continuing operations | ||||
| EBIT | $343.19 | -$24.75 | $326.75 | $286.44 |
| Income tax expense | $66.69 | -$11.61 | $57.08 | $39.43 |
| Interest expense | $67.16 | $69.16 | $64.29 | $82.33 |
| Net income | ||||
| Net income | $209.34 | -$82.31 | $205.38 | $164.68 |
| Income (for common shares) | $209.34 | -$82.31 | $205.38 | $164.68 |
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Net income | $49.07 | $49.46 | $53.05 | $53.56 |
| Operating activities | ||||
| Depreciation | $9.83 | $9.5 | $9.32 | $9.21 |
| Business acquisitions & disposals | -$10.56 | |||
| Stock-based compensation | $3.42 | $3.73 | $2.45 | $3.69 |
| Total cash flows from operations | $54.78 | $66.91 | $71.47 | $62.46 |
| Investing activities | ||||
| Capital expenditures | -$1.15 | -$3.14 | -$2 | -$2.93 |
| Investments | ||||
| Total cash flows from investing | -$2.13 | -$15 | -$4.5 | -$2.93 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$24 | $7.27 | $1.64 | $2.15 |
| Net borrowings | -$35.72 | -$74.95 | -$66.48 | -$55.7 |
| Total cash flows from financing | -$65.52 | -$68.44 | -$64.84 | -$53.55 |
| Effect of exchange rate | $0.66 | -$0.6 | $1.42 | -$0.49 |
| Change in cash and equivalents | -$12.21 | -$17.15 | $3.55 | $5.49 |
| (in millions $) | 31 Dec 2024 | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Net income | $209.34 | -$82.31 | $205.38 | $164.68 |
| Operating activities | ||||
| Depreciation | $36.82 | $38.94 | $38.8 | $37.25 |
| Business acquisitions & disposals | -$10.56 | -$247.05 | ||
| Stock-based compensation | $14.01 | $12.4 | $9.04 | $8.54 |
| Total cash flows from operations | $248.93 | $229.72 | $259.92 | $235.61 |
| Investing activities | ||||
| Capital expenditures | -$9.55 | -$7.78 | -$9.64 | -$22.24 |
| Investments | ||||
| Total cash flows from investing | -$20.11 | -$11.58 | -$256.51 | -$22.24 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$6.91 | -$42.63 | $7.04 | -$9.02 |
| Net borrowings | -$227.83 | -$137.75 | -$5.58 | -$251.44 |
| Total cash flows from financing | -$241.01 | -$185.85 | -$7.57 | -$279.42 |
| Effect of exchange rate | $0.18 | -$0.98 | -$0.96 | $3.6 |
| Change in cash and equivalents | -$12.02 | $31.3 | -$5.12 | -$62.46 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 1.00 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | N/A |
| Quick ratio | N/A |